TLR7 and glioma: Furthermore, researchers have developed a β-cyclodextrin nanoparticle (CDNP) formulation encapsulating the TLR7/8 agonist R848 (CDNP-R848), which reprograms myeloid cells in the glioma microenvironment to induce regression of syngeneic experimental gliomas and significantly improve survival rates (147).